FDA
-
-
-
-
-
-
-
Crinetics and Leading Patient Groups Launch ‘Everyday Advocacy’ Initiative to Empower People Across Endocrine Disease Communities
-
-
-
-
-
-
-
Crinetics submits marketing application for Palsonify in Brazil
-
-
-
-
-
-
-
Crinetics Pharmaceuticals Announces January 2026 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
-
-
-
-
-
-
-
Crinetics to announce atumelnant trial results and PALSONIFY update
-
-
-
-
-
-
-
Crinetics Announces First Patient Dosed in Phase 1/2 Trial Evaluating CRN09682 for the Treatment of Neuroendocrine Tumors and Other Somatostatin Receptor 2-Expressing Tumors
-
-
-
-
-
-
-
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025
-
-
-
-
-
-
-
Crinetics receives FDA orphan drug designation for CAH treatment
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

